2型糖尿病患者C反应蛋白与肾脏病变的相关性研究
Correlation Study between C-Reactive Protein and Renal Lesions in Patients with Type 2 Diabetes Mellitus
DOI: 10.12677/ACM.2023.1371504, PDF,   
作者: 辛 宇, 刘传峰*, 王颜刚#:青岛大学附属医院内分泌与代谢病科,山东 青岛
关键词: C反应蛋白2型糖尿病肾小球滤过率C-Reactive Protein Type 2 Diabetes Mellitus Glomerular Filtration Rate
摘要: 目的:探讨2型糖尿病(diabetes mellitus type 2, T2DM)患者C反应蛋白(C-reactive protein, CRP)与肾脏病变的关系,探讨CRP是否与糖尿病患者肾功能下降相关。方法:青岛大学医学院附属医院共招募6238名T2DM患者。通过调整潜在混杂变异后的逻辑回归分析,得到了与CRP四分位数相关的优势比(OR)和相应的95%置信区间(CI)。结果:根据CRP的四分位数,以CRP等于0.5、1.5、3.11切点,将CRP分为Q1、Q2、Q3、Q4组,Q1中T2DM患者的肾小球滤过率发生下降的概率几乎都大于其他三组(CKD2组:46.2% vs 34.38%,32.18%,33.61%,p < 0.05;CKD3组:23.19% vs 4.98%,4.37%,13.08%,p < 0.05;CKD4组:3.38% vs 2.17%,1.3%,2.85%,p < 0.05)。与Q4相比,Q1在CKD2、3、4组的OR值分别为2.613、3.37、2.259,p均< 0.05;而Q3在2、3、4组的OR值分别为0.797、0.276、0.378,p均< 0.05。调整收缩压、舒张压、年龄、高密度脂蛋白、低密度脂蛋白、胆固醇、尿酸后,与Q4相比,Q1在CKD2、3、4组的OR值分别为2.701、3.363、2.201,p值均< 0.05;而Q2、Q3在CKD2、3、4组的OR值均小于1且p < 0.05。在研究人群中,CRP与T2DM患者肾小球滤过率的水平呈U型关系。结论:在研究人群中,CRP水平与肾小球滤过率下降呈密切相关,这可能意味着,当CRP < 0.5 mg/L或>3.11 mg/L时是独立危险因素。
Abstract: Objective: To investigate the relationship between C-reactive protein (CRP) and renal lesions in type 2 diabetes mellitus (T2DM), and whether CRP is associated with the renal function decline in dia-betic patients. Methods: A total of 6238 T2DM patients were recruited from the Affiliated Hospital of Qingdao University School of Medicine. The odds ratio (OR) and the corresponding 95% confidence interval (CI) were obtained by logistic regression analysis after adjusting for potential confounding variants. Results: According to the quartile of the CRP, with CRP equal to 0.5, 1.5, 3.11 cut-points, CRP in groups Q1, Q2, Q3 and Q4, the probability of a decline in T2DM patients in Q1 was almost all greater than that in the other three groups (CKD2:46.2% vs34.38%, 32.18%, 33.61%, P < 0.05; CKD3 group: 23.19% vs 4.98%, 4.37%, 13.08%, p < 0.05; CKD4 group: 3.38% vs 2.17%, 1.3%, 2.85%, p < 0.05). Compared with Q4, the OR of Q1 in CKD2, 3 and 4 was 2.613, 3.37 and 2.259 re-spectively, all p < 0.05, while the OR of Q3 in groups 2, 3 and 4 was 0.797, 0.276 and 0.378 respec-tively and p < 0.05. After adjusting for systolic blood pressure, diastolic blood pressure, age, HDL, LDL, cholesterol, and uric acid, Q1 in CKD2 were 2.701 and 2.201 and 3.363, respectively, with p values < 0.05, compared with the Q4, while the Q 1 and Q2 in CKD2, 3 and 4 groups were less than 1 and p < 0.05. CRP and the level of glomerular filtration rate in T2DM patients in the study popula-tion. Conclusions: CRP levels were strongly associated with decreased glomerular filtration rate in the study population, which could be an independent risk factor when CRP < 0.5 mg/L or >3.11 mg/L.
文章引用:辛宇, 刘传峰, 王颜刚. 2型糖尿病患者C反应蛋白与肾脏病变的相关性研究[J]. 临床医学进展, 2023, 13(7): 10765-10772. https://doi.org/10.12677/ACM.2023.1371504

参考文献

[1] Cefalu, W.T., Xu, D., Long, J., Shi, Y., Zhang, L., Wang, H., Levin, A. and Zhao, M.-H. (2016) Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care, 39, 1186-1201. [Google Scholar] [CrossRef] [PubMed]
[2] Huang, Y.M., et al. (2019) Spectrum of Chronic Kidney Disease in China: A National Study Based on Hospitalized Patients from 2010 to 2015. Nephrology, 24, 725-736. [Google Scholar] [CrossRef] [PubMed]
[3] Sagoo, M. and Gnudi, L. (2020) Diabetic Nephropathy: An Overview. In: Gnudi, L. and Long, D., Eds., Diabetic Nephropathy, Methods in Molecular Biology, Vol. 2067, Humana, New York, 3-7. [Google Scholar] [CrossRef] [PubMed]
[4] Winiarska, A., et al. (2021) Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists. 22, Article 10822. [Google Scholar] [CrossRef] [PubMed]
[5] Liu, Y., Uruno, A., Saito, R., Matsukawa, N., Hishinuma, E., Saigusa, D., Liu, H. and Yamamoto, M. (2022) Nrf2 Deficiency Deteriorates Diabetic Kidney Disease in Akita Model Mice. Redox Biology, 58, Article ID: 102525. [Google Scholar] [CrossRef] [PubMed]
[6] Ren, H., Shao, Y., Wu, C., Ma, X., Lv, C. and Wang, Q. (2020) Metformin Alleviates Oxidative Stress and Enhances Autophagy in Diabetic Kidney Disease via AMPK/SIRT1-FoxO1 Pathway. Molecular and Cellular Endocrinology, 500, Article ID: 110628. [Google Scholar] [CrossRef] [PubMed]
[7] Zheng, W., Guo, J. and Liu, Z.S. (2021) Effects of Metabolic Memory on Inflammation and Fibrosis Associated with Diabetic Kidney Disease: An Epigenetic Perspective. Clinical Epigenetics, 13, Article No. 87. [Google Scholar] [CrossRef] [PubMed]
[8] Hojs, R., Ekart, R., Bevc, S. and Hojs, N. (2016) Markers of In-flammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients. Nephron, 133, 159-162. [Google Scholar] [CrossRef] [PubMed]
[9] Tian, S. and Chen, S.Y. (2015) Macrophage Polarization in Kidney Diseases. Macrophage, 2, e679.
[10] Niewczas, M.A., et al. (2019) A Signature of Circulating Inflammatory Proteins and Development of End-Stage Renal Disease in Diabetes. Nature Medicine, 25, 805-813. [Google Scholar] [CrossRef] [PubMed]
[11] Dong, Y., et al. (2019) High-Sensitivity C Reactive Protein and Risk of Cardiovascular Disease in China—CVD Study. Journal of Epidemiology & Community Health, 73, 188-192. [Google Scholar] [CrossRef] [PubMed]
[12] Hermans, M.P., Ahn, S.A. and Rousseau, M.F. (2019) Increased CRP: An Extended Biomarker of Microvascular Risk in Men with Type 2 Diabetes. Journal of Diabetes and its Com-plications, 33, Article ID: 107413. [Google Scholar] [CrossRef] [PubMed]
[13] Kugler, E., et al. (2015) C Reactive Protein and Long-Term Risk for Chronic Kidney Disease: A Historical Prospective Study. Journal of Nephrology, 28, 321-327. [Google Scholar] [CrossRef] [PubMed]
[14] Ren, H., Wu, C., Shao, Y., Liu, S., Zhou, Y. and Wang, Q. (2020) Correlation between Serum miR-154-5p and Urinary Albumin Excretion Rates in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Cohort Study. Frontiers of Medicine, 14, 642-650. [Google Scholar] [CrossRef] [PubMed]
[15] Mc Causland, F.R., et al. (2016) C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 68, 873-881. [Google Scholar] [CrossRef] [PubMed]
[16] Shankar, A., et al. (2011) Markers of Inflammation Predict the Long-Term Risk of Developing Chronic Kidney Disease: A Population-Based Cohort Study. Kidney International, 80, 1231-1238. [Google Scholar] [CrossRef] [PubMed]
[17] Cao, L., et al. (2019) Inflammation and Kidney Injury in Dia-betic African American Men. Journal of Diabetes Research, 2019, Article ID: 5359635. [Google Scholar] [CrossRef] [PubMed]
[18] Luo, F., et al. (2021) Systemic Immune-Inflammation Index Predicts the Outcome after Aneurysmal Subarachnoid hemorrhage. (Preprint) [Google Scholar] [CrossRef
[19] Microvascular Complications Group of Chinese Diabetes (2021) [Clinical Guideline for the Prevention and Treatment of Diabetic Kidney Disease in China (2021 Edition)]. Chinese Journal of Diabetes Mellitus, 13, 762-784. (In Chinese)
[20] Sudchada, P. and Laehn, S. (2016) Comparisons of GFR Estimation Using the CKD Epidemiology Collaboration (CKD-EPI) Equation and other Creatinine-Based Equations in Asian Population: A Systematic Review. International Urology and Nephrology, 48, 1511-1517. [Google Scholar] [CrossRef] [PubMed]
[21] Navarro-González, J.F., et al. (2011) Inflammatory Molecules and Pathways in the Pathogenesis of Diabetic Nephropathy. Nature Reviews Nephrology, 7, 327-340. [Google Scholar] [CrossRef] [PubMed]
[22] Pérez-Morales, R.E., et al. (2019) Inflammation in Diabetic Kidney Disease. Nephron, 143, 12-16. [Google Scholar] [CrossRef] [PubMed]
[23] Chow, F.Y., et al. (2005) Intercellular Adhesion Molecule-1 Deficiency Is Protective against Nephropathy in Type 2 Diabetic db/db Mice. Journal of the American Society of Nephrology, 16, 1711-1722. [Google Scholar] [CrossRef
[24] Choudhary, N. and Ahlawat, R.S. (2008) Interleukin-6 and C-Reactive Protein in Pathogenesis of Diabetic Nephropathy: New Evidence Linking Inflammation, Glycemic Control and Microalbuminuria. Iran J Kidney Dis, 2, 72-79.
[25] Zhou, Y., et al. (2019) Expression of Urokinase-Type Plas-minogen Activator Receptor and Its Soluble Form in Type 2 Diabetic Kidney Disease. Archives of Medical Research, 50, 249-256. [Google Scholar] [CrossRef] [PubMed]
[26] Gu, H., et al. (2012) Association of Intercellular Ad-hesion Molecule 1 (ICAM1) with Diabetes and Diabetic Nephropathy. Frontiers in Endocrinology, 3, Article 179. [Google Scholar] [CrossRef] [PubMed]
[27] Sanchez-Alamo, B., et al. (2022) Serum Interleukin-6 Levels Pre-dict Kidney Disease Progression in Diabetic Nephropathy. Clinical Nephrology, 97, 1-9. [Google Scholar] [CrossRef
[28] Al-Rubeaan, K., Nawaz, S.S., Youssef, A.M., Al Ghonaim, M. and Sid-diqui, K. (2019) IL-18, VCAM-1 and P-selectin as Early Biomarkers in Normoalbuminuric Type 2 Diabetes Patients. Future Medicine, 13, 467-478. [Google Scholar] [CrossRef] [PubMed]
[29] Zhong, Y., et al. (2019) Arctigenin Attenuates Diabetic Kidney Dis-ease through the Activation of PP2A in Podocytes. Nature Communications, 10, Article No. 4523. [Google Scholar] [CrossRef] [PubMed]
[30] Das, N.A., et al. (2020) Empagliflozin Reduces High Glu-cose-Induced Oxidative Stress and miR-21-Dependent TRAF3IP2 Induction and RECK Suppression and Inhibits Hu-man Renal Proximal Tubular Epithelial Cell Migration and Epithelial-to-Mesenchymal Transition. Cellular Signalling, 68, Article ID: 109506. [Google Scholar] [CrossRef] [PubMed]
[31] Du Clos, T.W. and Mold, C. (2004) C-Reactive Protein: An Ac-tivator of Innate Immunity and a Modulator of Adaptive Immunity. Immunologic Research, 30, 261-277. [Google Scholar] [CrossRef
[32] Krychtiuk, K.A., Kastl, S.P., Speidl, W.S. and Wojta, J. (2013) Inflamma-tion and Coagulation in Atherosclerosis. Hamostaseologie, 33, 269-282. [Google Scholar] [CrossRef
[33] Wang, L.-K., Wang, H., Wu, X.-L., Shi, L., Yang, R.-M. and Wang, Y.-C. (2020) Relationships among Resistin, Adiponectin and Leptin and Microvascular Complications in Patients with Type 2 Diabetes Mellitus. Journal of International Medical Research, 48. [Google Scholar] [CrossRef] [PubMed]
[34] You, Y.K., Wu, W.-F., Huang, X.-R., Li, H.-D., Ren, Y.-P., Zeng, J.-C. Chen, H. and Lan, H.Y. (2021) Deletion of Smad3 Protects against C-Reactive Protein-Induced Renal Fibro-sis and Inflammation in Obstructive Nephropathy. International Journal of Biological Sciences, 17, 3911-3922. [Google Scholar] [CrossRef] [PubMed]
[35] Pawluczyk, I.Z., Yang, B., Patel, S.R., Saleem, M.A. and Topham, P.S. (2011) Low-Level C-Reactive Protein Levels Exert Cytoprotective Actions on Human Podocytes. Nephrology Dialysis Transplantation, 26, 2465-2475. [Google Scholar] [CrossRef] [PubMed]